POLE and neoplasm: For the other three molecular subtypes, DFS did not show significant differences, as there were fewer cases of tumor progression log‐rank p > 0.99 (POLE‐mutant), p = 0.44 (MMR‐D), p = 0.50 (NSMP), (Figure S2).